Synta's Loss Widens 14% As It Reports Its Final Analysis From the GALAXY-1 Trial

Small-cap biopharmaceutical Synta Pharmaceuticals (NASDAQ: SNTA  ) generally pleased investors this morning by reporting its first-quarter earnings results and announcing the final analysis of its GALAXY-1 trial involving ganetespib in non-small cell lung cancer (in a separate press release).

Since Synta is a wholly clinical-stage company, it recorded no revenue for either the first quarter this year or in the prior year. Research and development costs, however, jumped 7% to $17.6 million, while selling, general, and administrative expenses rose 36% to $5.3 million.

The end result was a 14% increase in its net loss to $23.6 million, or $0.28 per share, compared to the $20.7 million loss, or $0.30 per share, reported in the year-ago quarter. Keep in mind, Synta had fewer shares outstanding last year, thus the higher EPS loss.

Cash is always important to follow for wholly clinical-stage companies, and Synta ended the quarter with $78.8 million in cash, cash equivalents, and marketable securities -- down from $91.5 million in the sequential fourth quarter. It did, however, net an additional $23 million in proceeds from common stock offerings since the end of the quarter, which gives the company ample cash to operate through at least the first half of 2015.

Synta also released its final analysis from the GALAXY-1 trial involving its Hsp90 inhibitor, ganetespib. According to that data, ganetespib was particularly effective in chemosensitive trial patients with an adjusted death risk reduction of 31% as it relates to overall survival, and an adjusted 26% benefit as it relates to progression-free survival. This chemosensitive group will be the basis for Synta's upcoming GALAXY-2 phase 3 trial. 


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2949542, ~/Articles/ArticleHandler.aspx, 12/18/2014 4:42:13 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement